# Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)

> **NCT06037889** · PHASE3 · COMPLETED · sponsor: **Peking Union Medical College Hospital** · enrollment: 516 (actual)

## Conditions studied

- Branch Atheromatous Disease

## Interventions

- **DRUG:** Tirofiban
- **DRUG:** Aspirin tablet
- **DRUG:** Clopidogrel tablet

## Key facts

- **NCT ID:** NCT06037889
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-09
- **Primary completion:** 2026-02-26
- **Final completion:** 2026-02-26
- **Target enrollment:** 516 (ACTUAL)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06037889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06037889, "Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06037889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*